Not yet recruiting
Phase 2b Study of VXB-221 and VXB-213 Protein Vaccine for Prevention of Respiratory Syncytial Virus and Human Metapneumovirus Infections in Adults ≥60 Years
Not yet recruitingInvestigational
Phase 2b Study of VXB-221 and VXB-213 Protein Vaccine for Prevention of Respiratory Syncytial Virus and Human Metapneumovirus Infections in Adults ≥60 Years
Investigational
- Substances:–
Countries:
Germany
Germany- Participants:18–64 years · 65+ years · Healthy volunteers
- Sponsor:Sanofi Pasteur Inc.



